Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression

References

• Lu KH, Lin RC, Yang JS, et al. Molecular and cellular mechanisms of melatonin in osteosarcoma. Cells. 2019;8(12):1618.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790.
   PubMed Web of Science ®Google Scholar
• Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer. 2005;104(5):1100–1109.
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Geller DS, Gill JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50.
   PubMed Web of Science ®Google Scholar
• Huo FC, Zhu ZM, Pei DS. N(6) -methyladenosine (m(6) A) RNA modification in human cancer. Cell Prolif. 2020;53(11):e12921.
   PubMed Web of Science ®Google Scholar
• Huang W, Chen TQ, Fang K, et al. N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021;14(1):117.
   PubMed Web of Science ®Google Scholar
• Zhu ZM, Huo FC, Pei DS. Function and evolution of RNA N6-methyladenosine modification. Int J Biol Sci. 2020;16(11):1929–1940.
   PubMed Web of Science ®Google Scholar
• Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74.
   PubMed Web of Science ®Google Scholar
• Lan Q, Liu PY, Bell JL, et al. The emerging roles of RNA m(6)A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. Cancer Res. 2021;81(13):3431–3440.
   PubMed Web of Science ®Google Scholar
• Uddin MB, Wang Z, Yang C. The m(6)A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis. Mol Cancer. 2021;20(1):61.
   PubMed Web of Science ®Google Scholar
• Miao W, Chen J, Jia L, et al. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. Biochem Biophys Res Commun. 2019;516(3):719–725.
   PubMed Web of Science ®Google Scholar
• Zhou L, Yang C, Zhang N, et al. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2. Biomed Pharmacother. 2020;125:109964.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou L, Wang Y. ALKBH5-mediated m(6)A demethylation of lncRNA PVT1 plays an oncogenic role in osteosarcoma. Cancer Cell Int. 2020;20:34.
   PubMed Web of Science ®Google Scholar
• Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887.
   PubMed Web of Science ®Google Scholar
• Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–726.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yu GL, Zhu X, et al. Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: implications in lipid metabolic disorders. Genes Dis. 2022;9(1):51–61.
   PubMed Web of Science ®Google Scholar
• Zhou LL, Xu H, Huang Y, et al. Targeting the RNA demethylase FTO for cancer therapy. RSC Chem Biol. 2021;2(5):1352–1369.
   PubMedGoogle Scholar
• Su R, Dong L, Li C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018;172(1–2):90–105 e123.
   PubMed Web of Science ®Google Scholar
• Khan K, Safi S, Abbas A, et al. Unravelling structure, localization, and genetic crosstalk of KLF3 in human breast cancer. Biomed Res Int. 2020;2020:1354381.
   PubMed Web of Science ®Google Scholar
• Pearson RC, Funnell AP, Crossley M. The mammalian zinc finger transcription factor Kruppel-like factor 3 (KLF3/BKLF). IUBMB Life. 2011;63(2):86–93.
   PubMed Web of Science ®Google Scholar
• Sun W, Hu S, Zu Y, et al. KLF3 is a crucial regulator of metastasis by controlling STAT3 expression in lung cancer. Mol Carcinog. 2019;58(11):1933–1945.
   PubMed Web of Science ®Google Scholar
• Yan M, Liu H, Xu J, et al. Expression of human Kruppel-like factor 3 in peripheral blood as a promising biomarker for acute leukemia. Cancer Med. 2020;9(8):2803–2811.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang Z, Zhang Y, et al. RNA sequencing analysis reveals protective role of kruppel-like factor 3 in colorectal cancer. Oncotarget. 2017;8(13):21984–21993.
   PubMedGoogle Scholar
• Sachdeva M, Dodd RD, Huang Z, et al. Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182. Cancer Lett. 2015;369(1):202–211.
   PubMed Web of Science ®Google Scholar
• Wu R, Liu Y, Yao Y, et al. FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(10):1323–1330.
   PubMed Web of Science ®Google Scholar
• Huo FC, Zhu ZM, Zhu WT, et al. METTL3-mediated m(6)A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2. Oncogene. 2021;40(16):2968–2981.
   PubMed Web of Science ®Google Scholar
• Mauer J, Jaffrey SR. FTO, m(6) Am, and the hypothesis of reversible epitranscriptomic mRNA modifications. FEBS Lett. 2018;592(12):2012–2022.
   PubMed Web of Science ®Google Scholar
• Xie H, Li J, Ying Y, et al. METTL3/YTHDF2 m(6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. J Cell Mol Med. 2020;24(7):4092–4104.
   PubMed Web of Science ®Google Scholar
• Chen J, Fang X, Zhong P, et al. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction. RNA Biol. 2019;16(8):991–1000.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhao X. Role of m6A in osteoporosis, arthritis and osteosarcoma (Review). Exp Ther Med. 2021;22(3):926.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Ying L, et al. Regulatory role of N6-methyladenosine (m(6)A) modification in osteosarcoma. Front Oncol. 2021;11:683768.
   PubMed Web of Science ®Google Scholar
• Liu H, Qin G, Ji Y, et al. Potential role of m6A RNA methylation regulators in osteosarcoma and its clinical prognostic value. J Orthop Surg Res. 2021;16(1):294.
   PubMed Web of Science ®Google Scholar
• Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol. 2000;32(11–12):1103–1121.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hao J, Zheng Y, et al. Role of Kruppel-like factors in cancer stem cells. J Physiol Biochem. 2015;71(1):155–164.
   PubMed Web of Science ®Google Scholar
• Ding F, Lai J, Gao Y, et al. NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression. Cancer Cell Int. 2019;19:217.
   PubMed Web of Science ®Google Scholar
• Kuppers DA, Arora S, Lim Y, et al. N(6)-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis. Nat Commun. 2019;10(1):4596.
   PubMedGoogle Scholar
• Chien CS, Li JY, Chien Y, et al. METTL3-dependent N(6)-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A. 2021;118(7).
   Google Scholar
• Ma D, Liu X, Zhang JJ, et al. Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020;7:592550.
   PubMed Web of Science ®Google Scholar
• Zhou C, Zhang Z, Zhu X, et al. N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine. 2020;59:102955.
   PubMed Web of Science ®Google Scholar
• Wang JY, Lu AQ. The biological function of m6A reader YTHDF2 and its role in human disease. Cancer Cell Int. 2021;21(1):109.
   PubMed Web of Science ®Google Scholar